Capricor Therapeutics, Inc. reported $22M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $22M (to Q4 2024). Net income: −$129M, trailing twelve months to Q2 2026. Free cash flow: −$115M, trailing twelve months to Q2 2026. EPS: −$2.45, trailing twelve months to Q2 2026.

CAPRCapricor Therapeutics, Inc.

Healthcare

$30.40+229% 1Y

$30.40

$3.8452 weeks$35.34

CAPR as reported

Capricor Therapeutics, Inc. reported $22M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$22M

Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied

Net income: −$129M
Net income · +85% year on year · trailing twelve months to Q2 2026
Free cash flow: −$115M
Free cash flow · +110% year on year · trailing twelve months to Q2 2026
EPS: −$2.45
EPS · +54% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CAPR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$22M	n/a	Q4 2024 · 6 quarters behind
Net income	−$129M	+85%	Q2 2026
EPS	−$2.45	+54%	Q2 2026
Operating margin	−286%	n/a	Q4 2024 · 6 quarters behind
Net margin	−274%	n/a	Q4 2024 · 6 quarters behind
ROE	−56%	n/a	Q2 2026
ROA	−41%	n/a	Q2 2026
ROIC	348%	n/a	Q4 2021 · 18 quarters behind
Free cash flow	−$115M	+110%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.